Perhaps one of the questions that will concern us in the future is not so much whether pulsed field ablation (PFA) represents the future of atrial fibrillation (AF) ablation—as this is already an established reality and the momentum is irreversible—but rather whether it will redefine the broader management of the disease. The real crux of the matter lies in whether this novel technology will fundamentally alter our clinical strategy regarding the comprehensive evaluation, treatment, and management of patients presenting with atrial fibrillation.
Historical Evolution of Guidelines and the "Point of No Return"
Historically, AF ablation, which originated at the turn of this century, progressed at a conservative pace before establishing itself in daily clinical practice, as reflected in official Society Guidelines:
- 2006: Ablation is first mentioned in the ACC/AHA/ESC Guidelines, receiving a Class IIa recommendation strictly for paroxysmal, drug-refractory AF, and only after antiarrhythmic drug therapy had failed.
- 2010: Despite numerous randomized controlled trials demonstrating the clear superiority of catheter ablation over antiarrhythmic drugs (AADs), the European recommendation remained stagnant at Class IIa. As a consolation, the authors granted a Class I recommendation to the ablation of common atrial flutter when documented prior to or during the AF procedure (a recommendation that, paradoxically, was downgraded to Class IIb years later).
- 2011–2012: Ablation receives a Class I recommendation for drug-refractory paroxysmal AF for the first time, initially in the American guidelines (2011) and subsequently in the European ones (2012), with the caveat that the procedure must be performed in experienced centers. Concurrently, catheter ablation as a first-line therapy (prior to antiarrhythmic drug trials) is tentatively introduced with a Class IIa recommendation.
- 2024: It took 12 consecutive years for ablation to be upgraded to a first-line therapy with a Class I recommendation in the ESC Guidelines (2024) [1]. This milestone change was supported by 6 randomized controlled trials (3 utilizing RF and 3 utilizing Cryo). Cryoballoon studies played a pivotal role, demonstrating that a straightforward, reproducible, and standardized technique, which is less operator-dependent, ensured superior outcomes in lesion durability and isolation maintenance.
This historical overview demonstrates how technological innovation can fundamentally reshape therapeutic approaches. In the exact same manner, the groundbreaking paradigm shift brought about by PFA over the past 3 years indicates that this modality possesses the dynamic potential to transform the treatment of atrial fibrillation once again, establishing additional indications backed by robust evidence from major upcoming clinical trials.
Biophysical & Histological Selectivity of Electroporation
PFA relies on the delivery of ultra-short, high-voltage electrical pulses (ranging from microseconds to milliseconds). Because thermal generation is proportional to the duration of energy delivery, PFA does not induce temperature elevation. Its mechanism of action involves the electroporation of the cell membrane, which leads to apoptosis.
Its profound clinical advantage lies in tissue selectivity. According to Schwan’s equation, the electroporation threshold depends on cell diameter. Atrial cardiomyocytes (diameter: 10–15 μm) have a lower energy threshold compared to esophageal smooth muscle cells (3–8 μm) or axons (2 μm). Consequently, effective myocardial ablation is achieved without collateral tissue injury.
Clinical Efficacy: From ADVENT to the SINGLE SHOT CHAMPION Trial
Initial clinical outcomes of PFA demonstrated an excellent 1-year success rate of approximately 70%:
- ADVENT Trial [2]: The first pivotal, randomized non-inferiority trial demonstrated non-inferior efficacy (~73.3%) between PFA (Farapulse) and conventional thermal sources (RF/Cryo). However, this trial slightly underrepresented the true efficacy of PFA, given that operators lacked prior clinical experience with the modality, unlike their extensive familiarity with thermal technologies.
- SINGLE SHOT CHAMPION Trial (2025) [3]: This recent study directly compared "one-shot" catheters (Cryoballoon vs. FARApulse) in paroxysmal AF. The results were highly encouraging, demonstrating a clear superiority of the FARApulse catheter in clinical efficacy (62.9% vs. 49.3% freedom from arrhythmia recurrence). Furthermore, PFA achieved shorter procedural times, reduced left atrial (LA) dwell times, and lower fluoroscopy dosages. This difference is attributed to the larger, more continuous, and contiguous lesions created by the FARApulse system.
The Challenge of Lesion Durability
Pulmonary vein (PV) reconnection has historically been the Achilles’ heel of thermal modalities. In repeat procedures (redos), the rates of permanently isolated veins are disappointingly low: a mere 19% in the FIRE AND ICE trial and 9.6% in the CIRCA-DOSE trial, with overall long-term vein durability failing to exceed 50%.
In the MANIFEST-REDO study (2025) [4], which evaluated patients returning to the electrophysiology lab following an initial PFA procedure, 45% of patients demonstrated durable isolation across all 4 pulmonary veins. The fact that a novel modality, utilized by operators who are still on the learning curve, achieves twice the durable isolation rate of older modalities (performed by expert operators) underscores the superiority of PFA. Additionally, the integration of pre-procedural or intra-procedural imaging (3D mapping, EnSite X, FARAVIEW) increased PV durability to 47% and posterior wall durability to 50%.
Within this framework, systems are continuously being refined to provide reliable real-time indicators of lesion efficacy and durability, offering immediate feedback to the electrophysiologist regarding ablation quality.
Persistent Atrial Fibrillation (Persistent AF): Toward a Shift in Indications
Currently, catheter ablation as a first-line option for persistent AF remains at a low level of recommendation (Class IIb) in current Guidelines due to a historical lack of large-scale randomized data. However, the publication of the AVANTGUARD trial in the New England Journal of Medicine rewrites the rulebook and paves the way for a guideline upgrade.
The AVANTGUARD trial [5] compared a first-line strategy using PFA (Farapulse system for concurrent PVI and posterior wall isolation – PWI) against conventional antiarrhythmic drug (AAD) therapy in patients with newly diagnosed persistent AF. Utilizing insertable cardiac monitors (ICMs) for continuous arrhythmia burden monitoring, the 12-month data demonstrated clear therapeutic superiority. Clinical success (freedom from recurrence, repeat ablation, or AAD therapy) reached 56.0% in the PFA cohort compared to just 30.1% in the drug cohort (Hazard Ratio: 0.46, p<0.001), representing a 54% reduction in the relative risk of treatment failure.
In the same context, the randomized SPHERE PER-AF trial [6] highlights a significant technological advancement, comparing a Dual-Energy system (the Sphere-9 catheter with the Affera platform) against the former gold standard of conventional radiofrequency: standard RF ablation with contact force sensing (Thermacool SmartTouch SF catheter with the CARTO system). This study revealed a clear trend toward improved clinical outcomes (73.5% treatment success in the Sphere-9 cohort versus 65.2% in the Thermacool control cohort, log-rank P=0.064), proving that procedural goals can be achieved more effectively, safely, and in significantly less procedural time.
These advancements render the complex and high-risk techniques of the past obsolete. Retrograde alcohol ablation of the vein of Marshall or hybrid surgical ablation (CONVERGE trial [7]) are anticipated to be downgraded in upcoming guidelines, as endocardial PFA and dual-energy systems now offer a simpler, safer, and superior alternative.
Safety Profile and Complication Management
While older thermal modalities were associated with a notable incidence of severe, unmanageable complications (e.g., atrio-esophageal fistulas, delayed cardiac tamponade due to localized inflammation), PFA transforms the safety landscape.
In the MANIFEST-17K study [8], which evaluated 17,642 patients, complications directly attributable to pulsed field energy delivery were virtually non-existent (0% esophageal events, 0% permanent phrenic nerve palsy, 0% pulmonary vein stenosis). The few severe complications reported (e.g., tamponade at 0.36%, stroke at 0.12%) related exclusively to mechanical catheter manipulation within the left atrium, indicating that they are inherent to operator technique and can be minimized.
The Future: Integrated Systems, Competition, and Cost Reduction
For the universal adoption of this method, manufacturers are developing comprehensive clinical ecosystems that feature:
- High-definition three-dimensional electroanatomical mapping (HD mapping).
- Single-shot catheters designed to optimize laboratory throughput and save valuable procedural time.
- Large-footprint catheters for efficient linear lesion creation, paired with conventional focal catheters for localized touch-ups.
- Hybrid systems capable of simultaneous or sequential RF and PFA delivery.
Although procedural costs remain elevated at present, intense competition among multiple medical device manufacturers—a dynamic not seen in monopolistic technologies such as leadless pacemakers or the S-ICD—guarantees a gradual decline in pricing. This will facilitate the widespread application of PFA in more complex and vulnerable patient cohorts (the elderly, individuals with heart failure, or those with severe comorbidities). The accumulation of this expanding clinical data will inevitably lead to rapid Guideline updates, permanently restructuring the global management of atrial fibrillation.
References
- Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen ML, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. Erratum in: Eur Heart J. 2025 Nov 3;46(41):4349. doi: 10.1093/eurheartj/ehaf306. PMID: 39210723.
- Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, Mountantonakis SE, Gibson DN, Harding JD, Ellis CR, Ellenbogen KA, DeLurgio DB, Osorio J, Achyutha AB, Schneider CW, Mugglin AS, Albrecht EM, Stein KM, Lehmann JW, Mansour M; ADVENT Investigators. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023 Nov 2;389(18):1660-1671. doi: 10.1056/NEJMoa2307291. Epub 2023 Aug 27. PMID: 37634148.
- Reichlin T, Kueffer T, Badertscher P, Jüni P, Knecht S, Thalmann G, Kozhuharov N, Krisai P, Jufer C, Maurhofer J, Heg D, Pereira TV, Mahfoud F, Servatius H, Tanner H, Kühne M, Roten L, Sticherling C; SINGLE SHOT CHAMPION Investigators. Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2025 Apr 17;392(15):1497-1507. doi: 10.1056/NEJMoa2502280. Epub 2025 Mar 31. PMID: 40162734.
- Scherr D, Turagam MK, Maury P, Blaauw Y, van der Voort P, Neuzil P, Reichlin T, Metzner A, Vijgen J, Kautzner J, Boveda S, Anic A, Hansen J, Manninger M, Sommer P, Anselme F, Willems S, Deneke T, Tilz R, Steven D, Wakili R, Jais P, Funasako M, Arentz T, Rollin A, Mulder BA, Ouss A, Petru J, Kueffer T, Lemoine MD, Koopman P, Peichl P, Adelino R, Jurisic Z, Ruwald M, Eberl AS, Sohns C, Savoure A, Nentwich K, Gunawardene M, Heeger CH, Sultan A, Bohnen JE, Kupusovic J, Derval N, Lehrmann H, Ekanem E, Reddy VY. Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study. Europace. 2025 Aug 4;27(8):euaf012. doi: 10.1093/europace/euaf012. PMID: 39824172; PMCID: PMC12344414.
- Wazni OM, Chun KRJ, Nair DG, Anic A, Duytschaever M, Chrispin J, Amin A, Ajijola OA, Gibson DN, Mansour M, Piccini JP, Natale A, Badin A, Osca J, Dukes J, Bhalla K, Hussein A, Senn T, Weiner S, Sood N, Dello Russo A, Sadhu A, Meyers J, Trulock K, Tam MTK, DeLurgio DB, Champagne J, Iacopino S, Kwan B, Albrecht EM, McCammon S, Garlitski AC, Sutton BS, Stein KM, Andrade JG; AVANT GUARD Study Investigators. Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation. N Engl J Med. 2026 Jun 25;394(24):2407-2418. doi: 10.1056/NEJMoa2600929. Epub 2026 Apr 25. PMID: 42041224.
- Anter E, Mansour M, Nair DG, Sharma D, Taigen TL, Neuzil P, Kiehl EL, Kautzner J, Osorio J, Mountantonakis S, Natale A, Hummel JD, Amin AK, Siddiqui UR, Harlev D, Hultz P, Liu S, Onal B, Tarakji KG, Reddy VY; SPHERE PER-AF Investigators. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med. 2024 Aug;30(8):2303-2310. doi: 10.1038/s41591-024-03022-6. Epub 2024 May 17. PMID: 38760584; PMCID: PMC11333282.
- DeLurgio DB, Crossen KJ, Gill J, Blauth C, Oza SR, Magnano AR, Mostovych MA, Halkos ME, Tschopp DR, Kerendi F, Taigen TL, Shults CC, Shah MH, Rajendra AB, Osorio J, Silver JS, Hook BG, Gilligan DM, Calkins H. Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial. Circ Arrhythm Electrophysiol. 2020 Dec;13(12):e009288. doi: 10.1161/CIRCEP.120.009288. Epub 2020 Nov 13. PMID: 33185144.
- Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P, Chierchia GB, Bulava A, Blaauw Y, Skala T, Fiala M, Duytschaever M, Szeplaki G, Schmidt B, Massoullie G, Neven K, Thomas O, Vijgen J, Gandjbakhch E, Scherr D, Johannessen A, Keane D, Boveda S, Maury P, García-Bolao I, Anic A, Hansen PS, Raczka F, Lepillier A, Guyomar Y, Gupta D, Van Opstal J, Defaye P, Sticherling C, Sommer P, Kucera P, Osca J, Tabrizi F, Roux A, Gramlich M, Bianchi S, Adragão P, Solimene F, Tondo C, Russo AD, Schreieck J, Luik A, Rana O, Frommeyer G, Anselme F, Kreis I, Rosso R, Metzner A, Geller L, Baldinger SH, Ferrero A, Willems S, Goette A, Mellor G, Mathew S, Szumowski L, Tilz R, Iacopino S, Jacobsen PK, George A, Osmancik P, Spitzer S, Balasubramaniam R, Parwani AS, Deneke T, Glowniak A, Rossillo A, Pürerfellner H, Duncker D, Reil P, Arentz T, Steven D, Olalla JJ, de Jong JSSG, Wakili R, Abbey S, Timo G, Asso A, Wong T, Pierre B, Ewertsen NC, Bergau L, Lozano-Granero C, Rivero M, Breitenstein A, Inkovaara J, Fareh S, Latcu DG, Linz D, Müller P, Ramos-Maqueda J, Beiert T, Themistoclakis S, Meininghaus DG, Stix G, Tzeis S, Baran J, Almroth H, Munoz DR, de Sousa J, Efremidis M, Balsam P, Petru J, Küffer T, Peichl P, Dekker L, Della Rocca DG, Moravec O, Funasako M, Knecht S, Jauvert G, Chun J, Eschalier R, Füting A, Zhao A, Koopman P, Laredo M, Manninger M, Hansen J, O’Hare D, Rollin A, Jurisic Z, Fink T, Chaumont C, Rillig A, Gunawerdene M, Martin C, Kirstein B, Nentwich K, Lehrmann H, Sultan A, Bohnen J, Turagam MK, Reddy VY. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med. 2024 Jul;30(7):2020-2029. doi: 10.1038/s41591-024-03114-3. Epub 2024 Jul 8. PMID: 38977913; PMCID: PMC11271404.
References
- Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen ML, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. Erratum in: Eur Heart J. 2025 Nov 3;46(41):4349. doi: 10.1093/eurheartj/ehaf306. PMID: 39210723.
- Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, Mountantonakis SE, Gibson DN, Harding JD, Ellis CR, Ellenbogen KA, DeLurgio DB, Osorio J, Achyutha AB, Schneider CW, Mugglin AS, Albrecht EM, Stein KM, Lehmann JW, Mansour M; ADVENT Investigators. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023 Nov 2;389(18):1660-1671. doi: 10.1056/NEJMoa2307291. Epub 2023 Aug 27. PMID: 37634148.
- Reichlin T, Kueffer T, Badertscher P, Jüni P, Knecht S, Thalmann G, Kozhuharov N, Krisai P, Jufer C, Maurhofer J, Heg D, Pereira TV, Mahfoud F, Servatius H, Tanner H, Kühne M, Roten L, Sticherling C; SINGLE SHOT CHAMPION Investigators. Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2025 Apr 17;392(15):1497-1507. doi: 10.1056/NEJMoa2502280. Epub 2025 Mar 31. PMID: 40162734.
- Scherr D, Turagam MK, Maury P, Blaauw Y, van der Voort P, Neuzil P, Reichlin T, Metzner A, Vijgen J, Kautzner J, Boveda S, Anic A, Hansen J, Manninger M, Sommer P, Anselme F, Willems S, Deneke T, Tilz R, Steven D, Wakili R, Jais P, Funasako M, Arentz T, Rollin A, Mulder BA, Ouss A, Petru J, Kueffer T, Lemoine MD, Koopman P, Peichl P, Adelino R, Jurisic Z, Ruwald M, Eberl AS, Sohns C, Savoure A, Nentwich K, Gunawardene M, Heeger CH, Sultan A, Bohnen JE, Kupusovic J, Derval N, Lehrmann H, Ekanem E, Reddy VY. Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study. Europace. 2025 Aug 4;27(8):euaf012. doi: 10.1093/europace/euaf012. PMID: 39824172; PMCID: PMC12344414.
- Wazni OM, Chun KRJ, Nair DG, Anic A, Duytschaever M, Chrispin J, Amin A, Ajijola OA, Gibson DN, Mansour M, Piccini JP, Natale A, Badin A, Osca J, Dukes J, Bhalla K, Hussein A, Senn T, Weiner S, Sood N, Dello Russo A, Sadhu A, Meyers J, Trulock K, Tam MTK, DeLurgio DB, Champagne J, Iacopino S, Kwan B, Albrecht EM, McCammon S, Garlitski AC, Sutton BS, Stein KM, Andrade JG; AVANT GUARD Study Investigators. Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation. N Engl J Med. 2026 Jun 25;394(24):2407-2418. doi: 10.1056/NEJMoa2600929. Epub 2026 Apr 25. PMID: 42041224.
- Anter E, Mansour M, Nair DG, Sharma D, Taigen TL, Neuzil P, Kiehl EL, Kautzner J, Osorio J, Mountantonakis S, Natale A, Hummel JD, Amin AK, Siddiqui UR, Harlev D, Hultz P, Liu S, Onal B, Tarakji KG, Reddy VY; SPHERE PER-AF Investigators. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med. 2024 Aug;30(8):2303-2310. doi: 10.1038/s41591-024-03022-6. Epub 2024 May 17. PMID: 38760584; PMCID: PMC11333282.
- DeLurgio DB, Crossen KJ, Gill J, Blauth C, Oza SR, Magnano AR, Mostovych MA, Halkos ME, Tschopp DR, Kerendi F, Taigen TL, Shults CC, Shah MH, Rajendra AB, Osorio J, Silver JS, Hook BG, Gilligan DM, Calkins H. Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial. Circ Arrhythm Electrophysiol. 2020 Dec;13(12):e009288. doi: 10.1161/CIRCEP.120.009288. Epub 2020 Nov 13. PMID: 33185144.
- Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P, Chierchia GB, Bulava A, Blaauw Y, Skala T, Fiala M, Duytschaever M, Szeplaki G, Schmidt B, Massoullie G, Neven K, Thomas O, Vijgen J, Gandjbakhch E, Scherr D, Johannessen A, Keane D, Boveda S, Maury P, García-Bolao I, Anic A, Hansen PS, Raczka F, Lepillier A, Guyomar Y, Gupta D, Van Opstal J, Defaye P, Sticherling C, Sommer P, Kucera P, Osca J, Tabrizi F, Roux A, Gramlich M, Bianchi S, Adragão P, Solimene F, Tondo C, Russo AD, Schreieck J, Luik A, Rana O, Frommeyer G, Anselme F, Kreis I, Rosso R, Metzner A, Geller L, Baldinger SH, Ferrero A, Willems S, Goette A, Mellor G, Mathew S, Szumowski L, Tilz R, Iacopino S, Jacobsen PK, George A, Osmancik P, Spitzer S, Balasubramaniam R, Parwani AS, Deneke T, Glowniak A, Rossillo A, Pürerfellner H, Duncker D, Reil P, Arentz T, Steven D, Olalla JJ, de Jong JSSG, Wakili R, Abbey S, Timo G, Asso A, Wong T, Pierre B, Ewertsen NC, Bergau L, Lozano-Granero C, Rivero M, Breitenstein A, Inkovaara J, Fareh S, Latcu DG, Linz D, Müller P, Ramos-Maqueda J, Beiert T, Themistoclakis S, Meininghaus DG, Stix G, Tzeis S, Baran J, Almroth H, Munoz DR, de Sousa J, Efremidis M, Balsam P, Petru J, Küffer T, Peichl P, Dekker L, Della Rocca DG, Moravec O, Funasako M, Knecht S, Jauvert G, Chun J, Eschalier R, Füting A, Zhao A, Koopman P, Laredo M, Manninger M, Hansen J, O’Hare D, Rollin A, Jurisic Z, Fink T, Chaumont C, Rillig A, Gunawerdene M, Martin C, Kirstein B, Nentwich K, Lehrmann H, Sultan A, Bohnen J, Turagam MK, Reddy VY. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med. 2024 Jul;30(7):2020-2029. doi: 10.1038/s41591-024-03114-3. Epub 2024 Jul 8. PMID: 38977913; PMCID: PMC11271404.